Strategic partnerships Mapp Biopharmaceutical is actively engaging with government and national programs (BARDA, HHS, Special Pathogens Network) to supply investigational Ebola therapies, presenting opportunities to position co-development, funding-aligned collaborations, and scaled manufacturing support for high-risk pathogens.

Ebola focus The company is centered on pan-ebolavirus antibody programs (MBP134) and has ongoing interest from U.S. officials and regulatory bodies for emergency use, suggesting sales avenues in emergency preparedness, clinical supply contracts, and externalization of manufacturing capabilities.

Expanded access readiness Mapp operates an expanded access policy for investigational products, indicating potential pilot programs, compassionate-use collaborations, and expedited access pathways that can be leveraged for strategic pilots with health systems and international partners.

Technology and collaborations Partnerships with ProBioGen for afucosylated antibody development and collaboration history with research networks imply a track record of CDMO and academic collaborations, offering avenues to position Mapp as a development and manufacturing partner for high-containment antibodies.

Funding and scale signals With revenue in the low tens of millions and a modest funding pool, there is potential to pursue co-investment opportunities, grants, and milestone-based deals with larger biopharma or public sector entities seeking infectious disease countermeasures.